Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma

Noopur Raje • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies CAR-T Dexamethasone

In this video, Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the challenges faced by clinicians when selecting therapies for patients with multiple myeloma who have relapsed after frontline therapy. Dr Raje also elaborates on the optimal sequencing of T-cell directed immunotherapies and their potential inclusion in the frontline setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Noopur Raje

2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023
2:29
Myeloma highlights at ASH 2022: BiTEs, CAR-T therapy, novel targets, and more
Noopur Raje • 11 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals